Abide Therapeutics

Our mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in Nature with validated, but mostly untapped therapeutic potential. Hundreds of serine hydrolases exist in humans and include lipases, amidases, esterases, thioesterases, proteases and peptidases, which all share a base-activated serine nucleophile that cleaves an amide or ester bond. Serine hydrolases play a key role in regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, life cycle of viruses and pathogens. The Abide technology selectively and near-universally targets this enzyme class in their native configuration for functional profiling and inhibitor discovery and optimization.
Company growth
Type
Private
HQ
San Diego, US
Founded
2011
Size (employees)
36 (est)-2%
Abide Therapeutics was founded in 2011 and is headquartered in San Diego, US

Key People at Abide Therapeutics

Alan Ezekowitz

Alan Ezekowitz

President, Co-Founder, CEO
Stan Blackburn

Stan Blackburn

CFO
Todd Jones

Todd Jones

VP

Abide Therapeutics Office Locations

Abide Therapeutics has offices in San Diego, Princeton
San Diego, US
Princeton, US

Abide Therapeutics Metrics

Abide Therapeutics Summary

Founding Date

2011

Total Funding

$2.25 M

Latest funding size

$2.25 M

Time since last funding

over 5 years
We estimate that Abide Therapeutics's latest funding round in November 2011 was $2.25 M. In total, Abide Therapeutics has raised $2.25 M
We estimate that Abide Therapeutics's current employees are approximately 40% female and 60% male.

Abide Therapeutics Company Life

You may also be interested in